	US 11,987,627 B2
	Anti-CD47 antibody and application thereof
Yong Wang, Jiangsu (CN); Liwen Zhao, Jiangsu (CN); Qifeng Song, Jiangsu (CN); Yongqiang Zhu, Jiangsu (CN); Yanan Zhang, Jiangsu (CN); Luwei Han, Jiangsu (CN); Liang Jin, Jiangsu (CN); and Wenming Wu, Jiangsu (CN)
Assigned to NANJING SANHOME PHARMACEUTICAL CO., LTD., Nanjing (CN)
Appl. No. 17/270,947
Filed by NANJING SANHOME PHARMACEUTICAL CO., LTD., Jiangsu (CN)
PCT Filed Aug. 30, 2019, PCT No. PCT/CN2019/103673 § 371(c)(1), (2) Date Feb. 24, 2021, PCT Pub. No. WO2020/043188, PCT Pub. Date Mar. 5, 2020.
Claims priority of application No. 201811009176.8 (CN), filed on Aug. 31, 2018.
Prior Publication US 2022/0119520 A1, Apr. 21, 2022
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 39/00 (2006.01)

CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

8 Claims

1. An anti-CD47 antibody or antigen-binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein

the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the amino acid sequences of HCDR1, HCDR2 and HCDR3 are set forth in SEQ ID NOs: 4, 5 and 6, respectively, and

the light chain variable region comprises LCDR1, LCDR2 and LCDR3, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 are set forth in SEQ ID NOs: 15, 16 and 17, respectively.